Global collaboration action on climate and health in sub-Saharan Africa

Overview

Funding for research consortia addressing climate-sensitive vector- and water-borne diseases in sub-Saharan Africa (SSA) and Europe, with a focus on clinical trials, implementation research, and health system resilience. Targets institutions with strong SSA representation and contributions from global partners to enhance impact.

Who Can Apply

Consortia comprising at least three independent legal entities from different countries, including:

• One entity from an EU Member State or Horizon Europe-associated country that is an EDCTP Association member.
• One entity from a sub-Saharan African EDCTP Association member country.

Additional partners from non-eligible countries may participate if their involvement is deemed essential.

Funding Details

• Maximum grant amount: 5,000,000 EUR.
• Total budget: Not specified.
• Co-funding: Proposals must leverage financial and/or in-kind contributions from contributing partners, equal to or exceeding the requested grant amount.

What Is Funded

Research on climate-sensitive vector- and water-borne diseases, including:

• Phase IIb/III clinical trials or post-authorisation (phase IV) trials for preventive/therapeutic medicines or vaccines.
• Large-scale implementation research on validated (TRL 8) medical devices or vector control interventions.
• Integration of One Health approaches, primary healthcare systems, and vulnerable populations (e.g., children, pregnant women, displaced communities).
• At least two of the following: indigenous populations, climate impact on supply chains, policy integration, or health system adaptations.

Technology / Maturity Requirements

• Medical devices or interventions must be validated at Technology Readiness Level (TRL) 8.
• Preclinical studies are out of scope unless they support clinical trial preparation (e.g., protocol development, lab test evaluation).

Key Dates

• Open date: 2026-01-13
• Deadline: 2026-03-03 (two-stage process; first-stage deadline not specified).

Application Process (High-Level)

• Two-stage process: First-stage proposals (non-anonymised) followed by full applications for shortlisted consortia.
• Contributing partners must submit a draft endorsement letter before the second-stage deadline.
• Applications submitted via the [Funding & Tenders Portal](https://ec.europa.eu/info/funding-tenders/opportunities/portal).

Post-Award Obligations

• Access plan: Mandatory submission of a strategy ensuring affordable, available, and accessible health technologies/services, including registration targets and demand planning.
• Annual reporting: Status updates on product development and exploitation for four years post-project.
• Exploitation obligations: Best efforts to broadly disseminate results; non-exclusive licensing may be required if results remain unexploited.
• Networking: Participation in joint activities (e.g., workshops, knowledge exchange) with other funded projects.

Geographic Scope & Language

• Eligible countries: EU Member States, Horizon Europe-associated countries, EDCTP Association members (SSA), and select non-eligible countries if participation is essential.
• Language: English.

Notes

• Scientific leadership: If the coordinator is not from SSA, a scientific project leader from an SSA EDCTP member country must be designated.
• Contributing partners: Must provide financial/in-kind contributions; their endorsement letters are reviewed by the Governing Board.
• Exclusions: Preclinical studies (unless preparatory for clinical trials) and proposals lacking SSA representation.